| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP & General Counsel
1 company
Anthony D'Adamio is SVP & General Counsel at BVS. Anthony D'Adamio's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Our model assigns Anthony D'Adamio a middling insider score of 61/100, based on 11 past trades. Over a 12-month horizon, 45.5% of those trades were profitable, with an average 12-month return of -3.8%.
The BVS filings lean toward selling, a net 58,911 shares.
Anthony D'Adamio has 28 Form 4 filings on record from February 2021 to April 2026, all as SVP & General Counsel at Bioventus (BVS), 2021–2026.
The 48 reported transactions were 16 option exercises, 15 option or other derivative awards, 11 open-market sales and 5 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $13K and 11 sales worth about $484K.
The only open-market purchase was 1,000 shares of BVS at an average $13.00 on February 11, 2021, about $13K.
The largest open-market sale was 16,016 shares of BVS at an average $11.19 on April 4, 2022, about $179K. Twelve months later BVS was down 92%.
7 of the 8 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 11, 2025 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 2,958 | $7.57 | $22,392.06 | -2.2% | -1.2% | +21.1% | |
| Mar 17, 2025 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 2,615 | $9.75 | $25,496.25 | -2.1% | -32.7% | -8.3% | |
| Feb 18, 2025 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 4,380 | $10.19 | $44,632.20 | -3.6% | -33.3% | -18.3% | |
| Dec 23, 2024 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 5,848 | $10.53 | $61,579.44 | -5.1% | -8.7% | -29.3% | |
| Jun 21, 2024 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 5,904 | $5.57 | $32,885.28 | -5.8% | +104.4% | +15.5% | |
| Jun 17, 2024 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 11,308 | $5.84 | $66,038.72 | -12.2% | +86.2% | +6.9% | |
| Apr 11, 2024 | BVS Bioventus Inc. | SVP & General Counsel | Sell10b5-1 | 3,054 | $4.75 | $14,506.50 | -5.0% | +22.5% | +55.5% | |
| Mar 15, 2024 | BVS Bioventus Inc. | SVP & General Counsel | Sell | 3,125 | $5.46 | $17,062.50 | -5.7% | +20.0% | +76.3% | |
| Mar 15, 2023 | BVS Bioventus Inc. | SVP & General Counsel | Sale+OE | 3,409 | $1.39 | $4,737.49 | -7.0% | +89.6% | +218.4% | |
| Apr 4, 2022 | BVS Bioventus Inc. | SVP & General Counsel | Sale+OE | 16,016 | $11.19 | $179,238.26 | -28.5% | -43.9% | -91.7% |